July 2016

Dear Supporters of Dawnrays Pharma,

I welcome you to our website and hope that the contents and information will aid you in gaining better understanding of our Group’s vision from different perspectives.

Dawnrays Pharma celebrated its 20th anniversary in 2015. Through twenty years of ups and downs, I am pleased that we had managed to weather the storms and the Group’s business has flourished in both size and technical achievement.

During the last decade, the pharmaceutical market in China has experienced rapid growth. In line with the industry’s performance, our Group has made significant progress in research and successfully developed and manufactured several medicinal products which are supplied to the domestic and international markets. These medicinal products have become leading brands in their respective curative areas and received high recognition by many users and the pharmaceutical market.

Our achievements in product research and development are all revolved around our concerns and attentiveness to users’ needs and benefits, the high importance of definite curative effect and product quality.

The current government policies brought various changes and improvements to the pharmaceutical industry in China. Looking forward, we will strive to capture emerging opportunities and overcome new challenges. We will continue to shoulder our share of responsibilities to society and to the pharmaceutical industry. We are committed to “Attend to Health, Persist in Creation” in making contributions to the health of mankind.


LI Kei Ling

Chairman and Executive Director

Dawnrays Pharmaceutical (Holdings) Limited

苏公网安备 32050602010200号